Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell therapy takes on autoimmune diseases

NCT ID NCT06733935

Recruiting now Disease control Sponsor: Nkarta, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it is safe and can reduce symptoms, though ongoing management may still be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis diffuse scleroderma myositis disease rheumatoid arthritis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IDIOPATHIC INFLAMMATORY MYOPATHIES RHEUMATOID ARTHRITIS SYSTEMIC SCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Nkarta Investigational Site

    RECRUITING

    Orange, California, 92868, United States

  • Nkarta Investigational Site

    RECRUITING

    Gainesville, Florida, 32601, United States

  • Nkarta Investigational Site

    WITHDRAWN

    Miami, Florida, 33133, United States

  • Nkarta Investigational Site

    RECRUITING

    Plantation, Florida, 33317, United States

  • Nkarta Investigational Site

    RECRUITING

    Chicago, Illinois, 60612, United States

  • Nkarta Investigational Site

    RECRUITING

    Fairway, Kansas, 66205, United States

  • Nkarta Investigational Site

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Nkarta Investigational Site

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Nkarta Investigational Site

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Nkarta Investigational Site

    RECRUITING

    Summit, New Jersey, 07302, United States

  • Nkarta Investigational Site

    RECRUITING

    New York, New York, 10007, United States

  • Nkarta Investigational Site

    RECRUITING

    Stony Brook, New York, 11794, United States

  • Nkarta Investigational Site

    RECRUITING

    Syracuse, New York, 13202, United States

  • Nkarta Investigational Site

    RECRUITING

    Charlotte, North Carolina, 28202, United States

  • Nkarta Investigational Site

    RECRUITING

    Dallas, Texas, 75201, United States

  • Nkarta Investigational Site

    RECRUITING

    Houston, Texas, 77002, United States

  • Nkarta Investigational Site

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Nkarta Investigational Site

    RECRUITING

    Manati, 00674, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.